



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/677,857	10/03/2003	Eugene R. Cooper	029318-0981	4616
31049 7590 02/23/2007 ELAN DRUG DELIVERY, INC. C/O FOLEY & LARDNER LLP 3000 K STREET, N.W. SUITE 500 WASHINGTON, DC 20007-5109			EXAMINER UNDERDAHL, THANE E	
			ART UNIT 1651	PAPER NUMBER
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		02/23/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

# Office Action Summary

Application No.

10/677,857

Applicant(s)

COOPER ET AL.

Examiner

Thane Underdahl

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 25 January 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-55 is/are pending in the application.
- 4a) Of the above claim(s) 11, 12 and 18-55 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-10 and 13-17 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>See Continuation Sheet</u> . | 6) <input type="checkbox"/> Other: _____  |

Continuation of Attachment(s) 3). Information Disclosure Statement(s) (PTO/SB/08), Paper No(s)/Mail Date :7/10/06, 2/4/04, 1/5/04, 10/3/03, 1/11/07.

Art Unit: 1651

### DETAILED ACTION

Applicant's response to the species election with traverse filed on 12/5/2006 is acknowledged. The applicant elected Group I which includes claims 1-17 and 52. Applicant has since withdrawn claim 52. The requirement for the election of a crystal type for the benzoyl peroxide composition from claim 2 is withdrawn. The required species elected are as follows:

Particle Size: Less than 1900 nm

Dosage Form: Cream

Benzoyl Peroxide Composition: about 99.5% to about 0.001%

Surface Stabilizer Composition: about 0.5% to about 99.999% by weight

Surface Stabilizer Type: Non-ionic

Active Agent: Antibiotics

The applicant traverses the restriction requirement on the grounds that no burden exists in examining the application. However the examiner is burdened to search both relevant patent and patent applications as well as non-patent literature in the examination of the claims.

Therefore, the Restriction/Election requirement is therefore made FINAL and the elected species and the claims they include will now be examined on the merits. These include claims 1-10 and 13-17. Claims 11 and 12 are withdrawn as being dependent from non-elected species.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ramirez et al. (U.S. Patent # 5,632,996, 1997).

These claims are drawn to a composition comprising particles of benzoyl peroxide (BP) or a salt thereof that is present in an amount from about 99.5% to about

Art Unit: 1651

0.001% by weight, wherein the particles have an average size of less than 2000 nm, and also contains a surface stabilizer is present in an amount of about 0.5% to 99.999% by weight. These particles can be in a crystalline phase, amorphous phase, a semi-crystalline phase, or a semi-amorphous phase. Claim 3 further limits claim 1 by requiring the BP particles be less than 1900 nm in size. Claim 4 limits the formulation of the composition in claim 1 to creams. The composition further comprises pharmaceutically acceptable excipients, carriers, or a combination thereof.

The surface stabilizer is selected from the group of non-ionic surface stabilizers. Claim 9 further limits that the composition of claim 1 comprises at least two surface stabilizers. Claim 10 provides a list to limit the surface stabilizers, some of which are ionic and non-ionic.

Ramirez et al. teach a composition of BP that ranges from 70% to 5% by weight and a surface stabilizer of alkylbenzoate (**AB**) that ranges in the composition from 95% to 30% by weight (col 3, lines 50-65, and col 2, lines 59-68). These BP compositions can be formulated into a lotion, cream or gel (lines 29-31). The cream compositions contain other non-ionic surface stabilizers AP such as well as colloidal silicon dioxide (col 4, line 40). The cream also contains pharmaceutically acceptable excipients and carriers such as glycolic acid and petrolatum (petroleum jelly).

Ramirez et al. also teach that their amorphous powder of BP is an art-defined equivalent to BP crystals in a cosmetic composition (col 3, line 28-46). Therefore it would be obvious for one of ordinary skill in the art to substitute one crystal phase of BP for another in a cosmetic formulation (M.P.E.P. § 2144.06).

What Ramirez et al. does not teach is the specific particle size of the BP in their composition. However one of ordinary skill in the art would recognize particle size is a result effective variable. Indeed Ramirez addresses particle size as important in the formulation by teaching "It would be desirable to provide a BP compositions...which have a smooth texture appropriate for cosmetic products" (col 1, lines 53-59) and BP "crystalline powder is gritty" and discusses the importance to "prepare a paste having benzoyl peroxide crystals that are sufficiently fine to be of acceptable texture for preparing products for topical use" (col 1, lines 30-40). Therefore one of ordinary skill in the art would recognize the importance of crystal size in the texture of a BP composition, and that finer crystals are required to reduce the grittiness of the composition to make it acceptable for topical use. One of ordinary skill in the art would also recognize from the teachings of Ramirez et al. that particle size can be adjusted to a desired texture. Therefore absent any teaching of criticality by the applicant concerning the particle size listed in claims 1 and 3 it would be *prima facie* obvious that one of ordinary skill in the art would recognize that the particle size in claims 1 and 3 is a result effective variable which is a matter of routine optimization ( M.P.E.P. § 2144.05 II).

Therefore the references listed above renders obvious claims 1-10.

Claims 1-10 and 14-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ramirez et al. (U.S. Patent # 5,632,996) as applied to claim 1-10 above, and further in view of Kanios et al. (U.S. Patent # 5,719,197, 1998).

Claims 1-10 are summarized above. Claims 14-16 further limit the composition of claim 1 by requiring the composition to be a bioadhesive, additionally comprise one or more non-BP active agents selected from the group of nutraceuticals, retinoic acid, antibiotics, sulfur and salicylic acid.

As mentioned above Ramirez et al. renders obvious claims 1-10 above by teaching a BP composition with a several surface stabilizers that can be formulated into a cream for cleansing the skin (col 1, lines 10-13) which includes acne treatment (col 4, lines 55-60). However Ramirez et al. does not teach the components of claims 13-17. These are taught in the by Kanios et al. Kanios et al. teach that their composition for topical applications of pharmaceutical agents and bioadhesive carriers can be formulated into an anti-acne composition containing BP and the additional active agent retinoic acid.

Since the anti-acne compositions of Ramirez et al. and Kanios et al. share common components to treat a common goal it would be obvious for one of ordinary skill in the art to add the composition of Ramirez et al. to the invention of Kanios. The motivation and reasonable expectation of success is provided by Kanios et al. who teach an anti-acne composition with similar components to Ramirez et al. Therefore, the invention as a whole would have been prima facie obvious at the time of filing in view of the references listed above and as such claims 1-10 and 14-16 are not allowable.

Claim 1-10 and 13-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ramirez et al. and Kanios et al. as applied to claims 1-10 and 14-16 above, and further in view of Bartnick et al. (U.S. Patent # 5,399,353, 1995).

Claims 1-10 as well as 14-16 are summarized above. Claim 13 further limits the composition of claim 1 by requiring the surface stabilizer is lysozyme, polyvinylpyrrolidone (**PVP**), benzalkonium chloride (**BKC**). Claim 17 limits the antibiotic to clindamycin or erythromycin.

Claims 1-10 are rendered obvious by Ramirez et al. Claims 1-10 and 14-16 are rendered obvious by the combination of Ramirez et al. and Kanios et al. While Kanios et al. does teach the addition of antibiotics clindamycin and erythromycin as well as lysozyme and PVP to their composition the motivation to add these components to a skin cleansing composition is provided by Bartnick et al.

Bartnick et al. teach a composition to disinfect undamaged skin (col 7, lines 15-20). In this composition they include strong disinfectants such as BP, lactic acid as well as PVP and lysozyme (col 7 line 65 to col 8 line 2). Ramirez et al. already adds the disinfectants lactic acid and BP to their composition (col 4, lines 35-45) and M.P.E.P. § 2144.06 states

"It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art."



Art Unit: 1651

Therefore it is *prima facie* obvious to one of ordinary skill in the art to add more disinfectants to the composition of Ramirez et al. and Kanios et al. as motivated by Bartnick et al.

Bartnick et al. also teach the addition of antibiotics to a composition to cleanse skin (col 7, line 62). Bartnick et al. is silent on which antibiotic. However Kanios et al. teach that the antibiotics clindamycin and erythromycin can be added to their skin composition (col 16, lines 63-65). One of ordinary skill in the art would recognize that antibiotics would be useful in treating skin diseases cause by bacterial infections such as acne. It would therefore have been obvious for the person of ordinary skill in the art to add the antibiotics of Kanios to the combined composition of Ramirez et al. and Kanios et al. The motivation is provided by Bartnick et al. who teach the additional components of a skin cleansing composition and the reasonable expectation of success is provided by the formulations of Kanios et al. Therefore, the invention as a whole would have been *prima facie* obvious at the time of filing in view of the references listed above and as such claims 1-10 and 13-17 are not allowable.

In summary no claims, as written, are allowed for this application.

**In response to this office action the applicant should specifically point out the support for any amendments made to the disclosure**, including the claims (MPEP 714.02 and 2163.06). Due to the procedure outlined in MPEP § 2163.06 for interpreting claims, it is noted that other art may be applicable under 35 U.S.C. § 102 or 35 U.S.C. § 103(a) once the aforementioned issue(s) is/are addressed.

Art Unit: 1651

Applicant is requested to provide a list of all copending U.S. applications that set forth similar subject matter to the present claims. A copy of such copending claims is requested in response to this Office action.

#### CONTACT INFORMATION

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thane Underdahl whose telephone number is (571) 272-9042. The examiner can normally be reached during regular business hours, 8:00 to 17:00 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached at (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Thane Underdahl

Leon B. Lankford Jr

*Leon B. Lankford Jr*  
AU 1651